Every material Form 8-K Marker Therapeutics, Inc. has filed with the SEC since November 14, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Marker Therapeutics said the FDA awarded it $2.6 million through its Orphan Products Clinical Trials grants program to support a Phase 1 study of MT-601 in patients with locally advanced unresectable pancreatic cancer. The company describes the funding as non-dilutive, and it expects clinical initiation of the study in the first quarter of 2027.
FDA award of $2.6 million under the Orphan Products Clinical Trials grants program, announced October 19, 2026
Grant will support a Phase 1 study of lead candidate MT-601 in locally advanced unresectable pancreatic cancer
FDA received 66 applications and selected six projects for funding in fiscal year 2026
Marker expects to begin clinical initiation of the pancreatic cancer study in the first quarter of 2027
Marker Therapeutics reported results for the year ended December 31, 2025, with grant income of $3.5 million, down from $6.6 million in 2024, and a net loss of $12.2 million, up from $10.7 million. The company said its existing cash and cash equivalents will fund operating expenses through the fourth quarter of 2026, assuming no additional grant funds are received.
Grant income was $3.5 million for 2025, versus $6.6 million for 2024.
Net loss was $12.2 million, or $0.79 per share, versus $10.7 million, or $1.19 per share, in 2024.
Research and development expenses were $11.8 million, versus $13.5 million in 2024; general and administrative expenses were $4.2 million, flat year over year.
Cash, cash equivalents and restricted cash were $17 million at December 31, 2025, which the company expects to fund operations through the fourth quarter of 2026.
Marker Therapeutics reported third quarter 2025 results on November 14, 2025. The net loss narrowed to $2.0 million from $2.3 million a year earlier, but grant income fell to $1.2 million from $1.9 million, and the nine-month net loss widened to $10.5 million from $6.9 million. The company said its cash will fund operations through the third quarter of 2026, assuming no additional grant funds, after raising approximately $10 million through its ATM facility.
Q3 2025 grant income was $1.2 million, down from $1.9 million in Q3 2024
Q3 2025 net loss was $2.0 million ($0.12 per share), versus $2.3 million ($0.26 per share) a year earlier
Cash and cash equivalents were $17.6 million at September 30, 2025, plus $1.4 million restricted cash
Nine-month net loss was $10.5 million versus $6.9 million, including a $453,135 loss on early termination of a vendor agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Marker Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →